Literature DB >> 6411129

Chromatofocusing of human high density lipoproteins and isolation of lipoproteins A and A-I.

A C Nestruck, P D Niedmann, H Wieland, D Seidel.   

Abstract

Using chromatofocusing, a column chromatography method with an internally generated pH gradient and focusing effects, human plasma high density lipoproteins (HDL) were fractionated into six subclasses within an interval of less than 1 pH unit (pH 5.1-4.2). All fractions floated in the ultracentrifuge at density = 1.21 g X ml-1, retained a typical HDL electron micrographic morphology and as a single band, alpha-migration on agarose electrophoresis. Compositional analysis of the subclasses revealed an inverse relationship between cholesterol ester and cholesterol on a molar basis. Distinct differences in the distribution of the apolipoproteins between the fractions were found. Two of the subclasses contained only apolipoprotein A-I and were therefore considered to be two forms of the lipid-combined form of apolipoprotein A-I, i.e., lipoprotein A-I. One subclass contained only apolipoproteins A-I + A-II and was, therefore, lipoprotein A. One subclass contained apolipoproteins A-I + A-II + D, and the two remaining contained additionally apolipoproteins C and E. Lipoprotein A-I was also demonstrated after immunoabsorption of apolipoprotein A-II-containing lipoproteins from whole serum. It is suggested that this method, which allows the fractionation of HDL into subclasses with distinct differences in apolipoprotein composition, offers new avenues for the study of the structural and metabolic heterogeneity of HDL.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411129     DOI: 10.1016/0005-2760(83)90099-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Speciated human high-density lipoprotein protein proximity profiles.

Authors:  Kekulawalage Gauthamadasa; Corina Rosales; Henry J Pownall; Stephen Macha; W Gray Jerome; Rong Huang; R A Gangani D Silva
Journal:  Biochemistry       Date:  2010-11-23       Impact factor: 3.162

2.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

3.  Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.

Authors:  J M Bard; G Luc; P Douste-Blazy; P Drouin; O Ziegler; B Jacotot; C Dachet; J L De Gennes; J C Fruchart
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

5.  Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.

Authors:  A K Walli; D Seidel
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

6.  ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator.

Authors:  Toshimi Kido; Kazuo Kondo; Hideaki Kurata; Yoko Fujiwara; Takeyoshi Urata; Hiroshige Itakura; Shinji Yokoyama
Journal:  Lipids Health Dis       Date:  2017-11-29       Impact factor: 3.876

7.  Bioinformatic Analysis of Plasma Apolipoproteins A-I and A-II Revealed Unique Features of A-I/A-II HDL Particles in Human Plasma.

Authors:  Toshimi Kido; Hideaki Kurata; Kazuo Kondo; Hiroshige Itakura; Mitsuyo Okazaki; Takeyoshi Urata; Shinji Yokoyama
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.